A&I Financial Services LLC bought a new position in shares of Organon & Co. (NYSE:OGN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 26,924 shares of the company's stock, valued at approximately $402,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Proficio Capital Partners LLC bought a new stake in shares of Organon & Co. in the 4th quarter worth approximately $394,000. Oppenheimer & Co. Inc. grew its holdings in shares of Organon & Co. by 70.8% during the fourth quarter. Oppenheimer & Co. Inc. now owns 32,278 shares of the company's stock worth $482,000 after purchasing an additional 13,379 shares during the last quarter. Fisher Funds Management LTD bought a new position in shares of Organon & Co. in the fourth quarter valued at about $1,897,000. Deseret Mutual Benefit Administrators raised its holdings in shares of Organon & Co. by 24.3% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 6,256 shares of the company's stock valued at $93,000 after buying an additional 1,222 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. acquired a new position in Organon & Co. during the 4th quarter worth about $2,820,000. 77.43% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on OGN shares. Barclays dropped their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. TD Cowen upgraded Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. Finally, Morgan Stanley dropped their target price on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating for the company in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $20.80.
Get Our Latest Analysis on Organon & Co.
Organon & Co. Stock Down 3.8 %
NYSE OGN traded down $0.56 during trading hours on Monday, hitting $14.35. 5,016,134 shares of the company traded hands, compared to its average volume of 2,975,340. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The business's 50-day moving average is $15.44 and its 200-day moving average is $17.10. The stock has a market capitalization of $3.70 billion, a price-to-earnings ratio of 4.31, a P/E/G ratio of 0.90 and a beta of 0.76. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10.
Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. Sell-side analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.
Organon & Co. Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be given a $0.28 dividend. The ex-dividend date is Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.80%. Organon & Co.'s payout ratio is 33.63%.
About Organon & Co.
(
Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
See Also
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
